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Background and aim: The progression of heart failure is affected by several factors, including chronic stimulation
of the β-adrenoceptor. This clinical study was designed to measure the effects of thoracic epidural analgesia (TEA)
on the plasma levels of norepinephrine (NE), cAMP, and cGMP in patients with heart failure and assess the clinical
implication of TEA.
Methods: Forty patients with heart failure were randomly assigned to TEA (TEA plus standard care) and control
groups (standard care). The plasma concentrations of cAMP, cGMP, brain natriuretic peptide (BNP), and NE were
measured using ELISA before treatment, the second and fourth weeks of treatment.
Results: The plasma concentrations of cAMP, cGMP, BNP, and NE in the TEA group were significantly reduced by
the fourth week compared to their initial concentrations (P < 0.01, for all parameters) and the control group (P < 0.05,
P < 0.05, P < 0.01, and P < 0.05, respectively). The values for left ventricular end diastolic diameter (LVEDD), ejection
fraction (EF), and fractional shortening (FS) in the TEA group improved significantly compared to their initial values and
the control group. However, the changes in levels for these indices in the control group were no statistical significant
compared to the initial levels.
Conclusions: TEA can effectively decrease the plasma concentrations of cAMP and cGMP and improve cardiac
function in patients with heart failure. The decreased levels of NE and cAMP occurred before the improvement in
cardiac function, indicating that the abnormal epidural signal transduction can be corrected in patients with heart
failure.
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Heart failure is the final stage for several types of heart
diseases and many related illnesses. Although the use of
cardiotonic drugs, diuretics, β-blockers, and angiotensin-
converting-enzyme inhibitors (ACEI) can improve the
cardiac function in patients with heart failure [1-3], the
morbidity and mortality of heart failure continues to
remain high [4,5]. Therefore, it is necessary to search for
new treatments for heart failure. In the past two decades,
extensive investigations have developed several effective
approaches for reducing the morbidity and mortality of
patients with congestive heart failure. These investigations* Correspondence: liqingshu1985@126.com
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reproduction in any medium, provided the orinclude pharmacological [2,3,6] and cardiac device the-
rapies [7], but significant improvement on the clinical
outcome has not been observed. Recently, cell-based ther-
apy has been demonstrated as an effective method for
treating heart failure in vitro and in vivo [8].
Sympathetic hyperactivity is a compensatory response
to cardiac function that can activate several signal trans-
duction pathways [9], but eventually becomes part of the
disease process and may result in decreasing cardiac
function. It was speculated that inhibiting the hyper-
active sympathetic nervous system would correct the
abnormal signal transduction and improve the cardiac
function in patients with heart failure. High thoracic epi-
dural analgesia (TEA) has been used extensively to treat
myocardial infarction patients with severe chest pain,d. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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blockading of cardiac sympathetic [10,11]. Kock et al.
have reported that TEA can improve the left ventricular
function during stress-induced myocardial ischemia in
patients with coronary artery disease [12]. In addition,
we have previously reported a beneficial outcome by one
patient treated with TEA [1]. Based on these preliminary
results, this study was designed to demonstrate the
therapeutic efficacy and safety of the TEA treatment in
a clinical trial setting. The results will be useful for
improving the clinical outcome of TEA in patients with
heart failure.
Methods
Patients and study design
The design for this study and clinical protocols were
reviewed and approved by the Ethics Committee of First
Affiliated Hospital of Harbin Medical University, Harbin,
China. All patients provided written informed consent
before participating in this study.
Forty patients with heart failure that were admitted to
our department between May 2010 and February 2011
were randomly divided into two groups: (1) the thoracic
TEA group and (2) the control group, using a computer-
generated random number. The classification was carried
out by experienced physicians who were unaware of the
group assignments for the patients and their laboratory
test results. The patients in the control group were
treated with conventional medications (e.g., digoxin,
diureticum, β-blockers, and ACEI), while patients in the
TEA group were treated with TEA in addition to con-
ventional medications. Overall, medications adminis-
tered to the two groups were similar, and includedβ-
blocker and ACE inhibitor.
Treatment procedure for thoracic epidural analgesia (TEA)
Blood pressure, oxygen saturation, and electrocardio-
gram were continuously monitored during placement of
the epidural catheter. While the patients were in a sit-
ting position, a thoracic epidural catheter was inserted at
the T4-T5 interspace, and then advanced 4–5 cm cepha-
lad until the T1-T2 interspace was reached. The catheter
was connected to a bacterial filter, which was changed
twice per week. Lidocaine was administered epidurally
(5 ml every 2 h from 9 a.m. to 11 p.m.) to induce block-
ade of cardiac sympathetic segments (T1-T5), which was
evaluated using cold discrimination with ice. We con-
firmed the catheter placement using a computed tomog-
raphy scan. The epidural top ups had been provided by
experienced physicians.
In addition to the standard care, patients in the TEA
group were administrated 0.5% lidocaine (5 ml every 2 h
from 9 a.m. to 11 p.m.) via the epidural catheter for four
weeks. Patients in the control group were placed withthe catheter and administrated 0.9% NaCl (5 ml every
2 h from 9 a.m. to 11 p.m.). The adequacy and level of
the block were established by confirming the loss of pin
prick sensation and warm/cold discrimination [13]. All
the patients tolerated the treatment, no additional ther-
apy was needed. If needed, the treatment may be admin-
istered for a period longer than four weeks. However, in
this study, we only used the data for a four-week period
for all the patients. The use of diuretics was decided by
the physicians who had no roles in the study design or
outcome evaluation.
Plasma sampling and analysis
Blood samples were collected in a tube containing ethylene
diamine tetra acetic acid (EDTA) from all the patients at
admission and at the second and fourth weeks during the
treatment process. Samples were immediately centrifuged
at 4°C, at 3000 rpm, and the plasma was collected and
stored at −80°C until being analyzed. Concentrations of
plasma cAMP and cGMP were measured using an ELISA
kit [Biocalvin Company, SuZhou, China] as instructed by
the manufacturer. ELISA also was used to assay the plasma
concentrations of norepinephrine (NE) and brain na-
triuretic peptide (BNP). The biochemical tests were per-
formed by experienced laboratory assistants that were
unaware of the group assignments for the patients and
other laboratory test results.
Cardiac ultrasonography
All patients underwent cardiac ultrasonography the day
prior to and following treatment. The left ventricular
end diastolic diameter (LVEDD), ejection fraction
(LVEF), and fractional shortening (FS) were measured at
these times. The ultrasonography was performed by an
experienced ultrasound technician. The GE Vivid5 color
ultrasonic diagnostic instrument was used, with the
probe frequency 1.7-3.6 MHz. By using M-type ultra-
sonic, we measured the ejection fraction, fractional
shortening, and left ventricular end diastolic diameter
for each patient.
Statistical analyses
Statistical analyses were performed using the statisitical
package SPSS 19.0 (SPSS Inc, Chicago, IL, USA).
Enumeration data were compared with the chi-square test.
Measurement data were presented as mean ± standard
deviation (SD) after a normality and homogeneity of vari-
ance test. A natural logarithm transform was performed
on the non-normal-distributed data. Multiple group com-
parisons were performed using one-way ANOVA analysis
of variance with Bonferroni correction. Comparisons of
changes in cardiac functions before and after treatment
between the TEA group and the control group were
performed using a two-tailed paired Student’s t test. The
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spective power analysis was performed for non-significant
results.Results
The baseline characteristics for patients in each group
are presented in Table 1. Forty patients (including 32
males and 8 females) with heart failure were randomly
divided into two groups: (1) the thoracic TEA group (in-
cluding 17 males and 3 females) and (2) the control
group (including 15 males and 5 females). In the TEA
group, there were five cases of coronary artery heart dis-
ease (CHD), four cases of hypertension, and 11 cases of
dilated cardiomyopathy (DCM); the corresponding cases
for these diseases in the control group were four, seven,
and nine, respectively. The patients were classified ac-
cording to the New York Heart Association as class IV
(consisting of 28 patients, 13 in the control group and
15 in the TEA group) and class III (consisting of 12 pa-
tients, 7 in the control group and 5 in the TEA group).
There were no statistical significance for baseline char-
acteristics between the two groups (p > 0.05).Plasma levels of NE, cAMP, cGMP, and BNP
Plasma levels of NE, cAMP, and cGMP in patients two
weeks after TEA treatment was initiated were signifi-
cantly lower than the pre-treatment levels (Figure 1);
plasma levels at four weeks were lower than at two
weeks. No significant changes were measured in the
control group for these parameters following standard
treatment (i.e., without TEA). Plasma levels of BNP in
the TEA group decreased significantly after treatment
compared to the initial levels, thus indicating that car-
diac function had significantly improved in this group.Table 1 Baseline characteristics of the patients with heart






Median (range) 69 (79-60) 68 (78-58)
Gender
Male 17 15 >0.05
Female 3 5
Concomitant diseases




III 5 7 >0.05
IV 15 13Clinical outcome
No significant changes were observed between the two
groups in the etiology of heart failure. The heart rate
and blood pressure of the patients in the TEA group
were decreased after the injection of lidocaine. The an-
gina and dyspnea and other signs of heart failure in
these patients gradually improved with the treatment.
After four weeks of treatment, the heart function by
each patient was re-evaluated. In both groups, heart
function improved compared to the initial measurement
but there was only a significant improvement in the
TEA group.
Based on test results for each treatment group, the
control group included 10 patients in class IV, six in
class III, and four in class II; the TEA group included
three patients in class IV, five in class III, and 12 in class
II. It is worth noting there was a statistically significant
difference between the two groups with respect to classi-
fication of the patients.
EF and FS increased, and the LVEDD decreased after
TEA treatment (Table 2), a finding consistent with
the clinical improvement of cardiac function. During
treatment, two patients in the TEA group had bleeding
complications, and one patient had infectious complication.
No patients had venous thromboembolism complication.
Discussion
Data that has previously been collected indicates the
activation of the sympathetic nervous system, as a com-
pensatory response to restore cardiac output, exists in
the early stage of heart failure, even prior to clinical
symptoms [14]. In addition, there is accumulating evi-
dence supporting the notion that chronic activation of
the sympathetic nervous system induces adverse effects
on cardiac contractile function. For example, Liang et al.
[15] reported that excessive sympathetic stimulation is
associated with the development of β-receptor down-
regulation and β-adrenergic sub-sensitivity in right heart
failure. Patel et al. [16] reported that chronic infusion of
NE caused myocardial hypertrophy, which reduced the
inotropic response to β-receptor stimulation. Excessive
levels of circulating catecholamines have been shown to
cause myocardial hypertrophy, myocyte damage, and
cardiomyopathy [4,17,18]. Based on these findings,
excessive sympathetic stimulation induced changes in
the noradrenaline-β-receptor-cAMP signal transduction
axis, damaged systolic function, and induced cardio re-
construction. Therefore, blocking excessive activated
sympathetic signal transduction may be an effective
approach to improve cardiac contractile function.
In recent years, patients with heart failure have been
treated with β-receptor blockers to block abnormal sym-
pathetic signal transduction, which has resulted in a
notable improvement in cardiac function and clinical
Figure 1 Plasma levels of NE (A), cAMP (B), cGMP (C), and brain natriuretic peptide (D) in the TEA groups and control groups after
4-weeks treatment. The data were transformed to a natural logarithm for a normal distribution. #: Significant change compared to pre-treatment by
one-way analysis of variance with Bonferroni correction (p < 0.05). Δ: Significant change compared to control group by one-way analysis of variance
with Bonferroni correction (p < 0.05).
Table 2 Changes in levels of cardiac function before and after four weeks treatment between the TEA group and
control group
GROUP LVEDD (mm) 95% CI EF (%) 95% CI FS (%) 95% CI NYHA 95% CI
Control group
Pre-treatment 64.85 ± 5.86 (53.56-76.13) 32.45 ± 7.21 (18.31-46.59) 25.80 ± 5.73 (14.56-37.04) 3.65 ± 0.48 (2.69-4.61)
post-treatment 63.15 ± 5.23 (52.89-73.40) 33.15 ± 5.98 (21.44-44.86) 26.61 ± 5.52 (15.73-37.37) 3.3 ± 0.8 (1.73-4.87)
Chang 1.65 ± 0.64 0.55 ± 0.38 0.85 ± 0.61 0.35 ± 0.10
TEA group
Pre-treatment 66.45 ± 5.28 (56.08-76.80) 30.35 ± 6.78 (13.23-46.78) 24.20 ± 3.54 (17.24-31.15) 3.75 ± 0.44 (2.87-4.62)
post-treatment 58.30 ± 5.38 (47.75-68.64) 34.15 ± 6.12 (16.39-50.42) 28.15 ± 4.67 (18.99-37.30) 2.55 ± 0.76 (1.06-4.04)
Chang 8.15 ± 0.65** 3.80 ± 0.56** 3.95 ± 0.62** 1.2 ± 0.16**
Significant differences were performed using a two-tailed paired Student t test. (**: p<0.001, vs. control group).
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of neurohormonal dysfunction is a rational therapeutic
approach in patients with chronic heart failure. Al-
though there is abundant evidence that demonstrates
sympathetic signal transduction is excessively stimulated
in patients with heart failure [20,21], there have been
few studies conducted to demonstrate the effects of the
blockade of the sympathetic signal transduction for
treating heart failure. In this study, abnormal sympathetic
signal transduction was blocked to explore the relation-
ships between heart failure and signal transduction. We
chose the intermittent injection scheme because it has a
reversible sympathetic nerve function and the timing may
avoid failing to recruit sympathetic drive when needed to
support cardiac function as a result of removal of sympa-
thetic nerve. The patients’ symptoms were improved all
day, also in the night without routine epidural injections.
Clinically relevant laboratory test parameters in combin-
ation with clinical and heart function observations were
used to measure the success of this treatment.
Results of this study demonstrated plasma concentra-
tions of NE, cAMP, and cGMP in patients with heart
failure within the TEA group were significantly lower
than the pre-treatment and showed a time-dependent
improvement. It is speculated that these results are in-
volved with the decrease in production of sympathetic
impulses, decreased synthesis and release of NE, inhib-
ition of NE-β-receptor-cAMP signal transduction, and
decreased synthesis and release of cAMP. As expected,
cardiac function of patients with heart failure improved
significantly with decreased concentrations in NE and
cAMP. This finding is in agreement with observations
made in several other studies [22,23] where the plasma
cAMP had a negative correlation with cardiac function.
It is well known that cGMP can reduce myocardial me-
tabolism, inotropy, and function [18,24]. The effects of
cGMP are mediated by direct inhibition of L-type Ca2+
channels, cGMP-dependent protein kinase, and cGMP-
regulated cAMP phosphodiesterases [24,25]. Therefore,
reduction of cGMP decreased its negative effects to the
myocardium and improved cardiac function. Down-
regulation of cAMP may be attributed to the inhibition of
downstream signals of NE after blocking the sympathetic
nerves, which results in the reduction of negative effects
on cardiac function. Furthermore, the decrease in levels of
plasma NE reduced the toxic effect to the myocardium
and is also associated with improvement in cardiac func-
tion. Therefore, it was concluded that the blockade of
sympathetic nerves corrected the abnormal signal trans-
duction in heart failure resulting in an improved cardiac
function.
BNP, which is synthesized and secreted by ventricular
myocardium, has been used as a heart failure marker
when the ventricular load and ventricular wall tensionare increased. In recent years, BNP has been recognized
to have a significant application value in the early diag-
nosis and assessment of severity, prognosis, and thera-
peutic outcome in patients with heart failure [26-29]. In
this study, levels of plasma BNP in the TEA group
decreased markedly after TEA treatment compared to
the initial levels, indicating that cardiac function was sig-
nificantly improved. This finding was consistent with
other biochemical parameters and clinical heart function
analyses.
TEA could lead to complications like hypotension, re-
spiratory depression, bleeding or hematomas, infectious
or abscesses, venous thromboembolism, paraplegia, and
even cardiac arrest. The most common complication
was hypotension, and the blood pressure patients had
improved after infusion. In this study, only one patient
in the TEA group had the complication of bleeding,
which was improved after the compression; no patients
withdrew from the study because of complications.
Conclusion
TEA may decrease the levels of plasma NE, cAMP, and
cGMP, the first messenger and second messenger of sig-
nal transduction, block the over-activated sympathetic
signal transduction, and improve cardiac systolic func-
tion. It is inferred that correcting abnormal signal trans-
duction through blocking the sympathetic nervous
system is a potential treatment for patients with heart
failure.
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